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In order to Improve the in wvo delivery of human protems destined for replacement therapy, a recombmant adenowrus contammg the cDNA 
sequence encodmg human a,-antitrypsin has been constructed and shown to dxect expressIon of the protem m the supernatant of human cell hnes. 
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1. INTRODUCTION 
cul-Antitrypsin (cYIAT) is a serum antiprotease which 
is mainly produced by hepatocytes and mononuclear 
phagocytes and whose major physiological function is 
to inhibit neutrophil elastase (NE) activity in the lung 
[ 11. NE is a serine protease capable of degrading pro- 
teins of the alveolar interstitium, the result of this ac- 
tion being the destruction of the lung parenchyma [2]. 
Severe hereditary deficiency of cv*AT is associated with 
low plasma and lung levels of cx,AT and predisposes af- 
fected individuals to pulmonary emphysema by impair- 
ing the protease/antiprotease balance in the lower 
respiratory tract [3,4]. 
CY~AT replacement is currently being assessed in the 
therapy of hereditary emphysema [5]. Large quantities 
of recombinant unglycosylated cvlAT have been made 
available by production in E. coli or yeast but the 
absence of sugar side chains results in a shorter plasma 
half-life [6-81. 
To circumvent this problem the product could be 
delivered directly to the site where the pathology of the 
deficiency is manifest, i.e. the alveolar epithelium. 
Aerosol administration of recombinant cv,AT has been 
shown to be effective in cu,AT-deficient patients [8,9]. 
Another possible approach is to implant in the lung 
autologous cells secreting ‘normal’ cvlAT or to deliver 
the correct cv,AT gene in situ via, for instance, a recom- 
binant viral vehicle infecting the lung epithelial cells. 
Correspondence uddress: M. Perricaudet, Gknktique des Virus On- 
co&es, lnstitut Gustave Roussy/PR 2, 39 Rue Camille Desmoulins. 
94805 Villejuif Cedex, France 
* Present addrex Research Department, Delta Biotechnology Ltd, 
Castle Court, Castle Boulevard, Nottingham NG7 IFD, UK 
60 
Published b.r Elsevrer Scrence Publishers B. I: (Blomedrcal Dw~sion) 
00145793/9O/S3.50 I<, 1990 Federation of European Biochemical Societies 
Both approaches rely on an efficient vector suited for 
high level and stable expression of cv,AT in exogenous 
cells. 
Retroviral vectors have recently been used to produce 
glycosylated recombinant cv,AT [lo]. Transformed 
fibroblasts have been implanted in the peritoneal cavity 
of nude mice and human (uIAT secreted by these cells 
has been detected in plasma and in the epithelial fluid 
of the lungs [ 1 I]. Although confirming the feasibility of 
the strategy, these experiments, however, demonstrated 
the need for improvement in the technology since the 
amounts of cv,AT produced by the retrovirus-infected 
cells were low. 
2. EXPERIMENTAL 
2 1 Consrructlon of the expressron plasrnld MLP-n/.-l T 
Plasmld MLP-u,AT contam the followng sequences inserted bet- 
ween the EcoRI and EatnHI restrlctlon sites of pBR322. (I) The 455 
base pairs of the left end of the human adeno~uxs (Ad) type 5 
genome (nucleotides l-455). This fragment carrle5 the Inverted Ter- 
minal Repeat, the’encapsldation ,lgnal Fequences and the enhancer of 
the EIA promoter. (ii) The major late promoter (MLP) of the human 
Ad type 2 (nucleotides 5780-6038). followed by an almost complete 
copy of the tripartite leader cDNA sequence (nucleottdec 6039-6079; 
7100&7171; 9634-9713) (iii) The complete human N,AT cDNA and 
(ic) the polyadenylatlon signal from the SV40 A gene (nucleotlde5 
2666-2533). 
2.2 Constructron of recombinant udenovirus 
The plasmid klLP-w,AT was dlgested wth Pstl and .-lccI ulthm 
the pBR322 sequence, and the ewsed fragment was cloned mto the 
unique C’laI site (map units 2.6) of Ad type 5, thus replacmg a portion 
of the viral EIA gene (Fig. I). To obtam an acceptable DNA 3lze for 
encapsidation, It was necessary to use an Ad deleted in the E3 region 
(d1327). which is not essential for the growth of the virus m vitro or 
m viva. After hgation, the DNA was uTed to transfect Ad type 
5-transformed human 293 cells [l2], using calcium phosphate 
precipltatlon [l3]. A recombinant adenocirus-n,AT (Ad-a,AT) was 
isolated after 7 days, as shown by DNA analysis. 
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Fig. 1. (A) Structure of the recombmant adenovtrus (Ad-curAT): the Ad5 d1327 derivative, which has the E3 region deleted, was used as vector 
for the chrmertc lrtAT transcrrption unit. (B) Enlarged is the left end of the recombinant genome containing the chimeric N~AT transcription unit: 
sequences correspondmg to the maJor late promoter (MLP) and to the triparttte leader (11, 12, 13) have been used to drive the transcription of 
the cvrAT cDNA and the SV40 mRNA processing signals. 
2.3. alAT expressron 
cvrAT expression was monitored by ELISA essentially as described 
in [14]. Goat anti-human ~YIAT (Cappel, Melvern, PA, USA) was us- 
ed as the primary and secondary antibody, the latter being tagged 
with peroxrdase. 
3. RESULTS AND DISCUSSION 
Transient expression of cviAT was tested in CHO 
cells after transfection with plasmid MLP-CX~AT. At 
25 h post-transfection, 2.5 yg/ml of @iAT were found 
in the supernatant (not shown). This demonstrated that 
the MLP directs the transcription of the cviAT cDNA 
into an mRNA that is efficiently transIated. 
Expression levels of cuiAT synthesized after Ad- 
cvrAT infection of 293 and HeLa cells are presented in 
Table I. Infection by the recombinant adenovirus at a 
multiplicity of 10 or 100 p.f.u. per cell led to accumula- 
tion of aiAT in the medium. After 6 days of infection 
with 100 p.f.u. of HeLa cells 60pg/ml of cviAT were 
detected. The results show that Ad can be used in vitro 
Table I 
Time course of extracellular (U~AT production 
Day 293 cells HeLa cells 
10 p.f.u. 100 p.f.u. 10 p.f.u. 100 p.f.u. 
1 1.933 3.937 0 0.625 
2 3.750 5.400 0.325 4.375 
3 4.250 5.050 3.800 41.250 
6 4.250 5.500 31.250 60.000 
The cumulative amounts of human cyr-antitrypsin (expressed in 
pg/ml) produced after mfection of 1 x lo7 293 and HeLa cells with 
IO or 100 p.f.u. of Ad-curAT virus 
to express high levels of human (YIAT. Amounts are 
higher for HeLa cells (which do not complement he 
EIA defect) than for 293 ceils where the recombinant 
virus can grow efficiently. This observation can be ex- 
plained by the fact that in HeLa cells the cellular 
machinery can transcribe the viral genes more efficient- 
ly as it is less compromised by the growth of the virus. 
4. CONCLUSION AND PROSPECTS 
With the goal of improving the expression of recom- 
binant glycosylated aiAT we have explored the use of 
an Ad vector. Ad vectors have proved useful for 
achieving high-level expression of a variety of foreign 
genes in different cell types [15-191. Ad infection in 
humans is benign and no neoplastic transformation has 
been associated. Here we report the construction of a 
recombinant Ad bearing the cDNA of the human cviAT 
under the control of the viral major late promoter. 
Since the ElA region is replaced, this vector is 
replication-defective unless propagated in human 293 
cells which complement he ElA defect, but can infect 
a variety of cell types where stable genomic integration 
of the viral sequences can occur. 
Our results argue in favor of the possibility of a 
recombinant adenovirus vector being used to correct in 
vivo arAT deficiency. 
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